SPECIAL NOTICE
65 -- Oncology Testing at Dallas VA Facility
- Notice Date
- 7/12/2021 8:40:44 AM
- Notice Type
- Special Notice
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- 257-NETWORK CONTRACT OFFICE 17 (36C257) ARLINGTON TX 76006 USA
- ZIP Code
- 76006
- Solicitation Number
- 36C25721Q1142
- Archive Date
- 08/11/2021
- Point of Contact
- Email: isela.loveless@va.gov, Isela Loveless - Contracting Officer, Phone: 210-694-6313
- E-Mail Address
-
Isela.Loveless@va.gov
(Isela.Loveless@va.gov)
- Awardee
- null
- Description
- Special Notice Notice of Intent to Award a Sole Source Procurement The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, intends to award a firm-fixed priced contract/order to Genomic Health, Inc. for Oncology testing: ITEM # DESCRIPTION CPT Code # EST QUANTITY NEEDED 1 Oncotype DX Breast 81519 48 2 Oncotype DX Prostate PLA 0047U 48 The requested items will be used for oncology testing of veteran patients by physicians orders. Genomic Health Inc provides the only FDA approved Oncotype DX-Breast test proven to predict chemotherapy benefit. The Oncotype DX test is included in all major cancer guidelines worldwide and is now considered as standard of care for women with early-stage breast cancer with unprecedented prospective patient outcomes in more than 50,000 patients from four large, independently run, international studies. This specific testing is needed for Veterans to start treatment earlier for better outcomes. The Oncotype DX Breast Cancer Assay for Ductal Carcinoma in Situ (DCK) and Ivasive Breast Cancer is offered exclusively by Genomic Health Inc. The Genomic Health Inc patent portfolio related to the Oncotype DX assay includes, but is not limited to, the following U.S. Patent Numbers: 7,081,340; 7,858,304; 7,838,224; 8,071,286; 8,329,398; 7,767,391; 7,569,345; 8,034,567; 8,206,919; 8,741,605; 7,939,261; 7,526,387; 7,871,769; 7,930,104 and 8,868,352. The patents are in full force and effect with the latest patent and Oncotype DX Genomic Prostate Score Assay anticipated to expire in 2028. The proposed order will be considered a standing order; where, the tests will be ordered throughout each period of performance, on an as-needed basis. This notice is not to be considered a request for quotations or proposals. A contract will not be awarded based on an offer received in response to this notice; however, all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 7 calendar days from the publication of this notice, a contract/order will be issued to Genomic Health Inc. without any further notice. The proposed contract actions are for reference lab testing, which the government intends to negotiate with only one source. The anticipated statutory authorities permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 8.4. The proposed sole source procurement will be made by a pricing agreement with Genomic Health Inc.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/ca60781b909d487e928f7a83bf3c65f1/view)
- Record
- SN06057668-F 20210714/210712230115 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |